And it depends on you how soon it will be developed
As equity investors caught up in the cannabis craze push pot stocks to record highs, options traders are paying the most ever to hedge against a comedown.
Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology - synthetic glucose binding molecules - for therapeutic and diagnostic applications.
Immunized people would transmit anti-malarial proteins to the insects that bite them, reducing spread of the deadly disease
$1.4M grant supporting development of foam with military, civilian applications for trauma care